Isomorphic Labs Targets $40 Billion Valuation as Alphabet’s AI Drug Venture Seeks Fresh Capital

Isomorphic Labs, Alphabet’s AI drug discovery company, is in early talks to raise more than $2 billion at a valuation of at least $40 billion. The financing could value the company as high as $50 billion, although discussions remain incomplete and terms can change, Bloomberg reported.

The proposed round would mark a sharp escalation in private-market expectations for AI companies working on scientific research. Isomorphic Labs was created in 2021 as a spinout from Google DeepMind and uses artificial intelligence to model biological systems, design drug candidates and support pharmaceutical development. The Economic Times and Dealroom also described the fundraising as exceeding $2 billion, while the company has not publicly confirmed the new valuation discussions.

Isomorphic Labs has already secured $2.1 billion in Series B funding, according to a company announcement and investor coverage. Thrive Capital led that round, with Alphabet and GV participating alongside MGX, Temasek, CapitalG and the UK Sovereign AI Fund. That financing was announced in May 2026 and was intended to move the company from developing foundational models toward applying them across drug design and development.

The reported new raise would come soon after that large capital injection, giving Isomorphic Labs substantial funding for global expansion, computing, research and clinical-development work. Company materials say the money is supporting its drug design engine and therapeutic pipeline. The cumulative financing figure is reported at about $2.7 billion across 3 rounds, according to the Multiples database, although private-company funding records can differ in timing and scope.

Isomorphic Labs gives Alphabet a direct vehicle for commercializing research associated with DeepMind’s advances in biology and machine learning. The company’s work centers on predictive and generative models that analyze protein structures, biological pathways and interactions relevant to medicines. Its stated goal is to shorten parts of the discovery process while producing drug candidates for pharmaceutical partners.

That model places Isomorphic Labs between software and biotechnology. Revenue depends on partnerships and successful programs, while value depends on scientific results that take years to validate. The company has worked with drugmakers including Eli Lilly on multiple targets, according to Multiples. A valuation above $40 billion would therefore attach a technology-company price to a business whose most important returns remain tied to laboratory testing, trials and regulatory approval.

The proposed valuation would reset expectations across AI-driven biotechnology by making scientific data, models and drug-development partnerships central investment assets. It would also intensify competition for researchers, specialized computing capacity and pharmaceutical collaborations. Isomorphic Labs’ progress gives large drugmakers another route into generative biology without building every model internally.

The company’s existing investor group spans technology, venture capital, sovereign funds and strategic capital. That mix reflects broad interest in AI applications beyond consumer software, but it also raises the standard for measurable results. A large private valuation will be judged against candidate quality, partner milestones and eventual clinical outcomes, rather than model demonstrations alone. The financing reports identify early discussions, so no new ownership structure or final valuation has been established.

The immediate milestone is a completed financing round with disclosed investors, terms and valuation. Bloomberg’s reporting says talks are at an early stage, while other coverage points to a raise above $2 billion. Until the transaction closes, the $40 billion figure remains a target discussed with prospective investors rather than a finalized company value.

Isomorphic Labs will also need to show that its drug design engine can produce commercial and clinical results at scale. The company says new capital will fund global operations and advance its pipeline. Investors will track pharmaceutical partnerships, candidate selection, laboratory validation and movement toward human trials. Those measures will determine whether the company’s private-market valuation reflects durable drug-development progress or the premium currently attached to leading AI research firms.